close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

14.96 +0.60 (+4.14%)
Streaming Delayed Price Updated: 3:15 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ↗
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
News headline image
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Recap: Phathom Pharmaceuticals Q3 Earnings ↗
 
Via Benzinga
News headline image
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity ↗
  
Via Benzinga
News headline image
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
What's Going On With Phathom Pharmaceuticals Stock? ↗
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo 
Via Benzinga
News headline image
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc. 
Via Benzinga
News headline image
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗
 
Via Benzinga
News headline image
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now ↗
One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
Via InvestorPlace
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
From Phathom Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today